fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
fincash number+91-22-62820123
All Best Performing Equity Mutual Funds 2020 | Fincash.com

Fincash » Mutual Funds » Best Equity Funds

Best Equity Mutual Funds To Invest In 2020

Updated on October 17, 2020 , 19528 views

An equity fund is a mutual fund that invests principally in stocks. It can be actively or passively (index fund) managed. Equity Funds are also known as stock funds.

Best Equity Funds

Equity funds should be the vehicle of choice when Investing for long-term goals. Equity funds have created huge profits for investors in the past few years. But as there is a wide choice before investors, choosing the right equity fund becomes critical. But with right qualitative and quantitative measures (discussed below), one can ideally choose the best equity Mutual Funds.

Why to Invest in Equity Funds?

1. Liquidity

Since stocks are actively traded across all major exchanges, every day, this makes equity funds a highly liquid investment. It provides investors, the convenience of buying and selling their stocks depending on the market situation. By investing in equity mutual funds, the money is usually credited to your bank account in 3 days.

2. Dividend Income

Investing into blue-chip companies may help investors earn a steady income in the form of dividends. A majority of such companies usually pay out regular dividends even in volatile market conditions, typically paid quarterly. Having a diversified portfolio can provide investors with a steady dividend income in the year.

3. Portfolio Diversification

With best equity mutual funds investors can diversify their portfolio through regularly investing. It means that they can invest in stocks of different economic sectors. So, even if a particular stock drops in value, the others may help investors make up for that loss depending on the market situation.

4. Ideal Investment Vehicle

In many ways, equity funds are ideal investment vehicles for investors that are not as well-versed in financial investing or do not possess a large amount of capital with which to invest. Equity funds are practical investments for most people.

The attributes that make equity funds most suitable for small individual investors are the reduction of risk resulting from a fund's portfolio diversification and the relatively small amount of capital required to acquire shares of an equity fund. A large amount of investment capital would be required for an individual investor to achieve a similar degree of risk reduction through diversification of a portfolio of direct stock holdings. Pooling small investors capital allows an equity fund to diversify effectively without burdening each investor with large capital requirements.

The price of the equity fund is based on the fund's net asset value (NAV) less its liabilities. A more diversified fund means that there is less negative effect of an individual stock's adverse price movement on the overall portfolio and on the share price of the equity fund.

Equity funds are managed by experienced professional portfolio managers, and their past performance is a matter of public record. Transparency and reporting requirements for equity funds are heavily regulated by the Security Exchange Board of India (SEBI)

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Top Equity Mutual Funds 2020

Best equity mutual funds are categorised according to its types- ELSS, Large cap funds, mid cap funds, Small cap funds, Diversified Funds, sector funds and Balanced Fund.

5 Best Large Cap Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
Axis Bluechip Fund Growth ₹32.04
↑ 0.25
₹17,2707.318.729.410.618.6
Kotak Bluechip Fund Growth ₹252.608
↑ 1.61
₹1,6788.928.15.45.57.514.2
ICICI Prudential Bluechip Fund Growth ₹42.44
↑ 0.46
₹23,4236.321.7-1.13.27.89.8
SBI Bluechip Fund Growth ₹39.9447
↑ 0.38
₹22,0587.722.9-0.92.56.911.6
DSP BlackRock TOP 100 Equity Growth ₹207.179
↑ 1.28
₹2,2977.321.8-3.91.35.814.8
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Mid Cap Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
Axis Mid Cap Fund Growth ₹42.22
↑ 0.03
₹6,7329.520.69.39.910.311.3
Invesco India Mid Cap Fund Growth ₹53.19
↑ 0.19
₹1,00510.323.811.6593.8
DSP BlackRock Midcap Fund Growth ₹61.39
↓ -0.04
₹8,27410.226.412.23.810.59.2
TATA Mid Cap Growth Fund Growth ₹147.794
↑ 0.60
₹86912.125.48.42.97.16.5
Kotak Emerging Equity Scheme Growth ₹41.222
↑ 0.22
₹7,53512.327.88.32.298.9
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Small Cap Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
SBI Small Cap Fund Growth ₹58.4498
↑ 0.46
₹5,32116.732.311.84.212.56.1
Kotak Small Cap Fund Growth ₹80.311
↑ 0.59
₹1,81121.840.714.928.35
Nippon India Small Cap Fund Growth ₹41.2523
↑ 0.28
₹9,62515.835.510.4-0.29.3-2.5
ICICI Prudential Smallcap Fund Growth ₹25.96
↑ 0.07
₹1,4371834.84-1.24.910
DSP BlackRock Small Cap Fund  Growth ₹59.66
↓ -0.01
₹5,32017.839.117.9-1.570.7
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Large & Mid Cap Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
Mirae Asset Emerging Bluechip Fund Growth ₹59.687
↑ 0.65
₹11,4661027.810.56.413.514.7
Invesco India Growth Opportunities Fund Growth ₹35.84
↑ 0.23
₹2,9609.423.41.64.8910.7
Tata Large and Midcap Fund Growth ₹216.429
↑ 1.56
₹1,634924.63.84.67.313.9
Edelweiss Large and Mid Cap Fund  Growth ₹33.045
↑ 0.20
₹5179.523.13.64.47.711.1
Kotak Equity Opportunities Fund Growth ₹128.819
↑ 0.73
₹3,757824.77.64.19.113.2
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Equity Linked Savings Schemes (ELSS)

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
Canara Robeco Equity Tax Saver Growth ₹74.81
↑ 0.21
₹1,18112.326.112.69.61010.7
Mirae Asset Tax Saver Fund Growth ₹19.67
↑ 0.23
₹4,27011.5309.87.4 14.1
Axis Long Term Equity Fund Growth ₹47.6212
↑ 0.27
₹21,8367.716.9-0.86.28.914.8
BOI AXA Tax Advantage Fund Growth ₹62.42
↑ 0.46
₹30915.228.217.55.810.114.6
Invesco India Tax Plan Growth ₹54.49
↑ 0.24
₹1,1348.4255.65.78.89.4
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Diversified/Multi Cap Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
Parag Parikh Long Term Equity Fund Growth ₹31.8698
↓ -0.08
₹4,79811.835.822.712.613.914.4
UTI Equity Fund Growth ₹161.63
↑ 0.37
₹11,38612.330.312.28.89.211.7
Canara Robeco Equity Diversified Growth ₹149.58
↑ 0.58
₹2,4139.523.79.37.89.312.3
Mirae Asset India Equity Fund  Growth ₹53.429
↑ 0.43
₹18,450926.23.55.11012.7
DSP BlackRock Equity Fund Growth ₹41.745
↑ 0.35
₹3,6686.218.704.48.617
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Sector Equity Mutual Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
UTI Healthcare Fund Growth ₹129.181
↓ -1.19
₹58617.232.363.9154.61.2
SBI Healthcare Opportunities Fund Growth ₹178.376
↓ -1.50
₹1,43416.832.361.512.12.8-0.5
Nippon India Pharma Fund Growth ₹227.169
↓ -2.62
₹3,91114.828.859.419.57.81.7
TATA India Pharma & Healthcare Fund Growth ₹13.5601
↓ -0.10
₹33716.427.452.816.6 5.5
ICICI Prudential Technology Fund Growth ₹84.13
↓ -0.31
₹6923380.743.52614.82.3
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Focused Equity Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
IIFL Focused Equity Fund Growth ₹18.8271
↑ 0.10
₹9639.925.2108.811.927.3
Axis Focused 25 Fund Growth ₹30.2
↑ 0.13
₹11,4558.122.916.411.214.7
SBI Focused Equity Fund Growth ₹146.465
↑ 1.15
₹10,1144.214.7-0.86.19.616.1
Motilal Oswal Focused 25 Fund  Growth ₹24.2781
↑ 0.26
₹1,2678.9214.65.28.417.1
Principal Focused Multicap Fund Growth ₹69.16
↑ 0.66
₹3995.7205.85.18.111.8
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Dividend Yield Equity Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
UTI Dividend Yield Fund Growth ₹67.6749
↑ 0.25
₹2,2335.922.93.23.97.33.3
Principal Dividend Yield Fund Growth ₹55.89
↑ 0.32
₹1686.821.65.63.49.54.4
Templeton India Equity Income Fund Growth ₹46.8975
↑ 0.01
₹79911.226.82.10.575.3
Aditya Birla Sun Life Dividend Yield Fund Growth ₹162.95
↑ 0.63
₹6786.223.15.2-2.83.13.5
ICICI Prudential Dividend Yield Equity Fund Growth ₹14.81
↑ 0.17
₹1592.321.4-5.5-5.53.7-2.9
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

5 Best Value Equity Funds

FundNAVNet Assets (Cr)3 MO (%)6 MO (%)1 YR (%)3 YR (%)5 YR (%)2019 (%)
UTI Value Opportunities Fund Growth ₹64.2439
↑ 0.44
₹4,3408.123.65.84.46.210.4
ICICI Prudential Value Discovery Fund Growth ₹147.99
↑ 1.07
₹15,7644.624.86.22.150.6
Nippon India Value Fund Growth ₹73.3026
↑ 0.53
₹2,8499.626.30.60.765.7
Tata Equity PE Fund Growth ₹137.855
↑ 1.46
₹4,4548.927.92.80.2105.3
Tata Equity P/E Fund Regular Plan - Dividend Trigger A (5%) Normal Dividend, Reinvestment ₹60.4467
↑ 0.64
₹4,4548.927.92.80.2105.3
Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 Oct 20

*Below is list of Equity Funds having AUM >= 50 Crore having best returns in last 1 Year.

1. UTI Healthcare Fund

(Erstwhile UTI Pharma & Healthcare Fund)

The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors.

UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a CAGR/Annualized return of 14.2% since its launch.  Ranked 40 in Sectoral category.  Return for 2019 was 1.2% , 2018 was -7.5% and 2017 was 6.2% .

Below is the key information for UTI Healthcare Fund

UTI Healthcare Fund
Growth
Launch Date 28 Jun 99
NAV (19 Oct 20) ₹129.181 ↓ -1.19   (-0.91 %)
Net Assets (Cr) ₹586 on 30 Sep 20
Category Equity - Sectoral
AMC UTI Asset Management Company Ltd
Rating
Risk High
Expense Ratio 2.77
Sharpe Ratio 1.79
Information Ratio 0.39
Alpha Ratio 7.99
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 15₹10,000
30 Sep 16₹9,340
30 Sep 17₹8,224
30 Sep 18₹8,901
30 Sep 19₹7,799
30 Sep 20₹12,984

UTI Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹340,450.
Net Profit of ₹40,450
Invest Now

Returns for UTI Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month -2.6%
3 Month 17.2%
6 Month 32.3%
1 Year 63.9%
3 Year 15%
5 Year 4.6%
10 Year
15 Year
Since launch 14.2%
Historical performance (Yearly) on absolute basis
YearReturns
2019 1.2%
2018 -7.5%
2017 6.2%
2016 -9.7%
2015 12.4%
2014 43.7%
2013 23.3%
2012 24.8%
2011 -9.6%
2010 37.4%
Fund Manager information for UTI Healthcare Fund
NameSinceTenure
V Srivatsa3 Mar 173.58 Yr.

Data below for UTI Healthcare Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Health Care92.82%
Basic Materials2.76%
Asset Allocation
Asset ClassValue
Cash4.42%
Equity95.58%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | 500124
11%₹64 Cr124,140
↓ -8,667
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA
11%₹62 Cr1,239,120
↓ -50,672
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
8%₹45 Cr148,420
↓ -29,385
Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087
7%₹43 Cr559,275
↑ 47,090
Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Jan 14 | 524494
6%₹36 Cr164,427
↓ -24,102
Cadila Healthcare Ltd (Healthcare)
Equity, Since 31 Jan 03 | 532321
6%₹34 Cr848,211
↑ 241,414
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Oct 13 | AUROPHARMA
4%₹25 Cr309,240
↓ -21,904
Eris Lifesciences Ltd Registered Shs (Healthcare)
Equity, Since 31 Mar 19 | 540596
4%₹24 Cr446,812
↓ -19,156
Biocon Ltd (Healthcare)
Equity, Since 31 Oct 18 | 532523
4%₹24 Cr533,700
↓ -12,684
Laurus Labs Ltd (Healthcare)
Equity, Since 30 Apr 20 | 540222
4%₹23 Cr786,180
↓ -365,340

2. SBI Healthcare Opportunities Fund

(Erstwhile SBI Pharma Fund)

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy.

SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a CAGR/Annualized return of 14.1% since its launch.  Ranked 34 in Sectoral category.  Return for 2019 was -0.5% , 2018 was -9.9% and 2017 was 2.1% .

Below is the key information for SBI Healthcare Opportunities Fund

SBI Healthcare Opportunities Fund
Growth
Launch Date 31 Dec 04
NAV (19 Oct 20) ₹178.376 ↓ -1.50   (-0.83 %)
Net Assets (Cr) ₹1,434 on 30 Sep 20
Category Equity - Sectoral
AMC SBI Funds Management Private Limited
Rating
Risk High
Expense Ratio 2.44
Sharpe Ratio 1.81
Information Ratio -0.14
Alpha Ratio 8.46
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-15 Days (0.5%),15 Days and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 15₹10,000
30 Sep 16₹9,571
30 Sep 17₹8,069
30 Sep 18₹8,329
30 Sep 19₹7,208
30 Sep 20₹11,813

SBI Healthcare Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹323,701.
Net Profit of ₹23,701
Invest Now

Returns for SBI Healthcare Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month -1.8%
3 Month 16.8%
6 Month 32.3%
1 Year 61.5%
3 Year 12.1%
5 Year 2.8%
10 Year
15 Year
Since launch 14.1%
Historical performance (Yearly) on absolute basis
YearReturns
2019 -0.5%
2018 -9.9%
2017 2.1%
2016 -14%
2015 27.1%
2014 56.8%
2013 26%
2012 37.1%
2011 -5.5%
2010 29.1%
Fund Manager information for SBI Healthcare Opportunities Fund
NameSinceTenure
Tanmaya Desai1 Jun 119.34 Yr.

Data below for SBI Healthcare Opportunities Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Health Care97.22%
Basic Materials0.38%
Asset Allocation
Asset ClassValue
Cash2.4%
Equity97.6%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 20 | 500124
11%₹156 Cr300,000
↑ 20,000
Lupin Ltd (Healthcare)
Equity, Since 31 Jul 18 | 500257
10%₹141 Cr1,400,000
Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 500087
10%₹139 Cr1,800,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA
8%₹119 Cr1,500,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
8%₹110 Cr360,000
↑ 8,140
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA
7%₹100 Cr2,000,000
↓ -500,000
Strides Pharma Science Ltd (Healthcare)
Equity, Since 31 Mar 14 | STAR
5%₹65 Cr900,000
↓ -100,000
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 31 Dec 19 | NH
4%₹57 Cr1,600,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 20 | APOLLOHOSP
3%₹47 Cr220,000
Sequent Scientific Ltd (Healthcare)
Equity, Since 31 Jul 14 | 512529
3%₹46 Cr3,000,000

3. Nippon India Pharma Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a CAGR/Annualized return of 21% since its launch.  Ranked 35 in Sectoral category.  Return for 2019 was 1.7% , 2018 was 3.6% and 2017 was 7.6% .

Below is the key information for Nippon India Pharma Fund

Nippon India Pharma Fund
Growth
Launch Date 5 Jun 04
NAV (19 Oct 20) ₹227.169 ↓ -2.62   (-1.14 %)
Net Assets (Cr) ₹3,911 on 30 Sep 20
Category Equity - Sectoral
AMC Nippon Life Asset Management Ltd.
Rating
Risk High
Expense Ratio 2.33
Sharpe Ratio 1.67
Information Ratio 1.02
Alpha Ratio 4.83
Min Investment 5,000
Min SIP Investment 100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 15₹10,000
30 Sep 16₹9,404
30 Sep 17₹8,381
30 Sep 18₹10,297
30 Sep 19₹9,129
30 Sep 20₹14,672

Nippon India Pharma Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹367,070.
Net Profit of ₹67,070
Invest Now

Returns for Nippon India Pharma Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month -2.8%
3 Month 14.8%
6 Month 28.8%
1 Year 59.4%
3 Year 19.5%
5 Year 7.8%
10 Year
15 Year
Since launch 21%
Historical performance (Yearly) on absolute basis
YearReturns
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%
2013 20.9%
2012 34.8%
2011 -11%
2010 31.9%
Fund Manager information for Nippon India Pharma Fund
NameSinceTenure
Sailesh Raj Bhan1 Apr 0515.51 Yr.
Kinjal Desai25 May 182.35 Yr.

Data below for Nippon India Pharma Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Health Care96.75%
Asset Allocation
Asset ClassValue
Cash3.25%
Equity96.75%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
10%₹403 Cr4,000,025
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
10%₹391 Cr4,910,000
↑ 610,000
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
10%₹380 Cr7,600,976
↑ 400,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124
10%₹376 Cr725,000
↓ -85,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
9%₹366 Cr1,200,075
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
9%₹364 Cr4,700,000
Thyrocare Technologies Ltd (Healthcare)
Equity, Since 31 May 16 | THYROCARE
6%₹216 Cr2,854,919
↑ 25,811
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Aug 18 | 532843
5%₹195 Cr14,403,541
Cadila Healthcare Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321
4%₹158 Cr3,998,982
Sanofi India Ltd (Healthcare)
Equity, Since 30 Jun 04 | 500674
4%₹151 Cr175,000

4. DSP BlackRock World Gold Fund

"The primary investment objective of the Scheme is to seek capital appreciation by investing predominantly in units of MLIIF - WGF. The Scheme may, at the discretion of the Investment Manager, also invest in the units of other similar overseas mutual fund schemes, which may constitute a significant part of its corpus. The Scheme may also invest a certain portion of its corpus in money market securities and/or units of money market/liquid schemes of DSP Merrill Lynch Mutual Fund, in order to meet liquidity requirements from time to time. However, there is no assurance that the investment objective of the Scheme will be realized."

DSP BlackRock World Gold Fund is a Equity - Global fund was launched on 14 Sep 07. It is a fund with High risk and has given a CAGR/Annualized return of 5.8% since its launch.  Ranked 11 in Global category.  Return for 2019 was 35.1% , 2018 was -10.7% and 2017 was -4% .

Below is the key information for DSP BlackRock World Gold Fund

DSP BlackRock World Gold Fund
Growth
Launch Date 14 Sep 07
NAV (16 Oct 20) ₹21.0257 ↑ 0.02   (0.08 %)
Net Assets (Cr) ₹860 on 30 Sep 20
Category Equity - Global
AMC DSP BlackRock Invmt Managers Pvt. Ltd.
Rating
Risk High
Expense Ratio 1.32
Sharpe Ratio 0.94
Information Ratio -1.09
Alpha Ratio -6.56
Min Investment 1,000
Min SIP Investment 500
Exit Load 0-12 Months (1%),12 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 15₹10,000
30 Sep 16₹18,559
30 Sep 17₹15,414
30 Sep 18₹12,951
30 Sep 19₹17,118
30 Sep 20₹25,362

DSP BlackRock World Gold Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹470,047.
Net Profit of ₹170,047
Invest Now

Returns for DSP BlackRock World Gold Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month -7.1%
3 Month 2.4%
6 Month 28.7%
1 Year 57.6%
3 Year 18.4%
5 Year 17%
10 Year
15 Year
Since launch 5.8%
Historical performance (Yearly) on absolute basis
YearReturns
2019 35.1%
2018 -10.7%
2017 -4%
2016 52.7%
2015 -18.5%
2014 -3%
2013 -41.5%
2012 -5.8%
2011 -2.6%
2010 29%
Fund Manager information for DSP BlackRock World Gold Fund
NameSinceTenure
Jay Kothari1 Mar 137.59 Yr.

Data below for DSP BlackRock World Gold Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Basic Materials91.07%
Asset Allocation
Asset ClassValue
Cash5.3%
Equity92.22%
Debt0.04%
Other2.44%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
BGF World Gold I2
Investment Fund | -
97%₹835 Cr2,224,850
↑ 242,297
Treps / Reverse Repo Investments / Corporate Debt Repo
CBLO/Reverse Repo | -
5%₹41 Cr
Net Receivables/Payables
Net Current Assets | -
2%-₹16 Cr

5. TATA India Pharma & Healthcare Fund

The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a CAGR/Annualized return of 6.5% since its launch.  Return for 2019 was 5.5% , 2018 was -2.6% and 2017 was 4.7% .

Below is the key information for TATA India Pharma & Healthcare Fund

TATA India Pharma & Healthcare Fund
Growth
Launch Date 28 Dec 15
NAV (19 Oct 20) ₹13.5601 ↓ -0.10   (-0.75 %)
Net Assets (Cr) ₹337 on 30 Sep 20
Category Equity - Sectoral
AMC Tata Asset Management Limited
Rating Not Rated
Risk High
Expense Ratio 2.61
Sharpe Ratio 1.68
Information Ratio 0.82
Alpha Ratio 9.46
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-3 Months (0.25%),3 Months and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 16₹9,501
30 Sep 17₹8,151
30 Sep 18₹9,101
30 Sep 19₹8,790
30 Sep 20₹13,560

TATA India Pharma & Healthcare Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹458,689.
Net Profit of ₹158,689
Invest Now

Returns for TATA India Pharma & Healthcare Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month -3.1%
3 Month 16.4%
6 Month 27.4%
1 Year 52.8%
3 Year 16.6%
5 Year
10 Year
15 Year
Since launch 6.5%
Historical performance (Yearly) on absolute basis
YearReturns
2019 5.5%
2018 -2.6%
2017 4.7%
2016 -14.7%
2015
2014
2013
2012
2011
2010
Fund Manager information for TATA India Pharma & Healthcare Fund
NameSinceTenure
Rahul Singh20 Apr 200.45 Yr.
Meeta Shetty20 Apr 200.45 Yr.

Data below for TATA India Pharma & Healthcare Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Health Care96.56%
Asset Allocation
Asset ClassValue
Cash3.44%
Equity96.56%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 500124
15%₹52 Cr100,300
↓ -14,000
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA
10%₹35 Cr690,100
↓ -180,000
Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087
9%₹32 Cr410,000
↑ 42,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB
8%₹28 Cr92,500
↓ -10,000
Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 524494
7%₹24 Cr109,500
↑ 14,500
Narayana Hrudayalaya Ltd (Healthcare)
Equity, Since 29 Feb 20 | NH
7%₹22 Cr626,720
↑ 200,000
Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 500257
6%₹20 Cr203,000
↑ 25,000
Laurus Labs Ltd (Healthcare)
Equity, Since 31 Jul 20 | 540222
5%₹16 Cr560,000
↑ 245,000
Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Jul 18 | 500126
4%₹13 Cr26,000
Indoco Remedies Ltd (Healthcare)
Equity, Since 30 Jun 20 | 532612
3%₹11 Cr445,000
↑ 265,000

6. Franklin India Feeder - Franklin U S Opportunities Fund

The Fund seeks to provide capital appreciation by investing predominantly in units of Franklin U. S. Opportunities Fund, an overseas Franklin Templeton mutual fund, which primarily invests in securities in the United States of America.

Franklin India Feeder - Franklin U S Opportunities Fund is a Equity - Global fund was launched on 6 Feb 12. It is a fund with High risk and has given a CAGR/Annualized return of 19.7% since its launch.  Ranked 6 in Global category.  Return for 2019 was 34.2% , 2018 was 6.5% and 2017 was 18.1% .

Below is the key information for Franklin India Feeder - Franklin U S Opportunities Fund

Franklin India Feeder - Franklin U S Opportunities Fund
Growth
Launch Date 6 Feb 12
NAV (16 Oct 20) ₹47.6283 ↓ -0.14   (-0.30 %)
Net Assets (Cr) ₹2,252 on 30 Sep 20
Category Equity - Global
AMC Franklin Templeton Asst Mgmt(IND)Pvt Ltd
Rating
Risk High
Expense Ratio 1.56
Sharpe Ratio 1.61
Information Ratio 0.1
Alpha Ratio 3.64
Min Investment 5,000
Min SIP Investment 500
Exit Load 0-3 Years (1%),3 Years and above(NIL)

Growth of 10,000 investment over the years.

DateValue
30 Sep 15₹10,000
30 Sep 16₹10,530
30 Sep 17₹12,077
30 Sep 18₹16,537
30 Sep 19₹16,178
30 Sep 20₹23,415

Franklin India Feeder - Franklin U S Opportunities Fund SIP Returns

   
My Monthly Investment:
Investment Tenure:
Years
Expected Annual Returns:
%
Total investment amount is ₹300,000
expected amount after 5 Years is ₹481,656.
Net Profit of ₹181,656
Invest Now

Returns for Franklin India Feeder - Franklin U S Opportunities Fund

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Oct 20

DurationReturns
1 Month 6%
3 Month 9.9%
6 Month 33%
1 Year 48.1%
3 Year 25.8%
5 Year 18.6%
10 Year
15 Year
Since launch 19.7%
Historical performance (Yearly) on absolute basis
YearReturns
2019 34.2%
2018 6.5%
2017 18.1%
2016 -0.8%
2015 8.8%
2014 8.4%
2013 55.2%
2012
2011
2010
Fund Manager information for Franklin India Feeder - Franklin U S Opportunities Fund
NameSinceTenure
Mayank Bukrediwala24 Aug 200.1 Yr.

Data below for Franklin India Feeder - Franklin U S Opportunities Fund as on 30 Sep 20

Equity Sector Allocation
SectorValue
Technology27.56%
Health Care16.4%
Financial Services14.27%
Consumer Cyclical13.14%
Communication Services7.96%
Industrials5.83%
Real Estate5.79%
Consumer Defensive2.2%
Basic Materials1.21%
Asset Allocation
Asset ClassValue
Cash1.75%
Equity94.72%
Other3.52%
Top Securities Holdings / Portfolio
NameHoldingValueQuantity
Franklin US Opportunities I(acc)USD
Investment Fund | -
100%₹2,253 Cr4,631,642
↑ 111,337
Call, Cash & Other Assets
CBLO | -
0%-₹1 Cr

Smart Tips to Choose Best Equity Funds for 2020

A perfect way to invest in the best equity mutual funds is by looking at its both qualitative and quantitative measures.

1. Qualitative Measures

a. Know Your Fund Manager

The credit of performance of a Mutual Fund scheme lies with the fund manager. A fund manager is responsible for making investment decisions for the fund’s portfolio. So, investors should go through the performance of the funds managed by the particular fund manager, especially during the tough market phases. Also, investors should give more priority to a fund manager who has an experience of managing a similar kind of funds, for example- small and mid caps. Going for a fund manager who has been consistent over his career is a preferred choice.

b. Fund House Reputation

While choosing the best equity mutual funds to invest, always look at the quality & reputation of the fund house. A fund house with a long-standing record, large assets under management, star funds or good performing fund etc., is the one to invest in. Hence a fund house having a strong presence in the financial industry with a consistent track record should be ideally preferred.

2. Quantitative Measures

a. Fund Performance

An investor should do a fair assessment of the funds’ performances for over a period of time. Also, it is suggested to go for a fund that consistently beats its benchmark over 4-5 years, additionally, one should see each period and see if the fund is able to beat the benchmark or not.

b. Size of the Fund

Investors should always go for a fund that is neither too big nor too small in size. While there is no perfect definition and relation between the size of the fund, it is said that both too small and too large, can hinder a fund’s performance. Thus, while choosing a fund, it is advisable to go for the one whose AUM (Asset Under Management) is approximately same as the category.

3. Additional Quantitative Measures

a. Expense Ratio

Investors who have Mutual Fund Investments have to bear certain charges like operation costs, management fees, etc., charged by the Asset Management Company (AMC). Generally, the expense ratio is higher for schemes that are actively managed than it is for passively managed schemes (such as Index Funds or ETFs). As per the SEBI rules, an expense ratio for equity funds are a minimum of 2.5%.However, the expense ratio is something which should not supersede other important factors such as fund performance etc. It is better to pay a higher expense ratio in a fund knowing that it will beat it competitors by a good margin.

b. Ratio Analysis

Some of the important ratios to measure fund performance are:

c. Alpha

Alpha is a measure of the success of your investment or rather outperformance against the benchmark. It measures on how much the fund or stock has performed in the general market. A positive alpha of 1 means that the fund has outperformed its benchmark index by 1%, while a negative alpha of -1 would indicate that the fund has produced 1% lower returns than its market benchmark. So, basically, an investor’s strategy should be to buy securities with positive alpha.

d. Beta

It measures volatility in a stock’s price or fund relative to a benchmark and is denoted in positive or negative figures. A Beta of 1 signifies that the stock’s price moves in line with the market, beta of a greater than 1 designates that the stock is riskier than the market, and a beta of less than 1 means that the stock is less risky than the market. So, lower beta is better in a falling market. In a rising market, high-beta is better.

e. Standard Deviation (SD)

In simple terms, SD is a statistical measure representing the volatility or risk in an instrument. The higher the SD, higher will be the fluctuations in the returns.

f. Sharpe Ratio

Sharpe Ratio measures returns (both negative & positive) with respect to the risk taken. Here the risk is defined by the Standard Deviation. A higher Sharpe ratio means, a higher return without too much risk. Thus, while investing, investors should choose a fund that shows a higher Sharpe ratio.

g. Sortino Ratio

The Sortino Ratio is a variation of Sharpe Ratio. But, unlike Sharpe ratio, Sortino ratio considers only the downside or negative return. Such a ratio is helpful for investors to assess risk in a better manner than just looking at the returns to the total volatility.

Upside Capture Ratio & Downside Capture Ratio

Upside/downside capture ratio guide an investor- whether a fund is outperformed i.e. gained more or lost less than a broad market benchmark- during the phase of the market upside (strong) or downside (weak), and more importantly by how much. Well, an upside ratio of over 100 means that a given fund has beaten the benchmark during the period of positive returns. And a downside ratio of less than 100 shows that a given fund has lost less than its benchmark during the phase of dull returns. So, generally, investors should go for a fund that has a lower downside capture ratio and a higher upside capture ratio.

Equity Fund Taxation

As per the Budget 2018 speech, a new Long Term Capital Gains (LTCG) tax on equity oriented mutual funds & stocks will be applicable from 1st April. The Finance Bill 2018 was passed by voice vote in Lok Sabha on 14th March 2018. Here’s how new income tax changes will impact the equity investments from 1st April 2018.

1. Long Term Capital Gains

LTCGs exceeding INR 1 lakh arising from redemption of Mutual Fund units or equities on or after 1st April 2018, will be taxed at 10 percent (plus cess) or at 10.4 percent. Long-term capital gains till INR 1 lakh will be exempt. For example, if you earn INR 3 lakhs in combined long-term capital gains from stocks or Mutual Fund investments in a financial year. The taxable LTCGs will be INR 2 lakh (INR 3 lakh - 1 lakh) and tax liability will be INR 20,000 (10 per cent of INR 2 lakh).

Long-term capital gains are the profit arising from selling or redemption of equity funds held more than a year.

2. Short Term Capital Gains

If Mutual Fund units are sold before one year of holding, Short Term Capital Gains (STCGs) tax will apply. The STCGs tax has been kept unchanged at 15 percent.

Equity Schemes Holding Period Tax Rate
Long Term Capital Gains (LTCG) More than 1 Year 10% (with no indexation)*****
Short Term Capital Gains (STCG) Less than or equal to a year 15%
Tax on Distributed Dividend - 10%#

*Gains up to INR 1 lakh are free of tax. Tax at 10% applies to gains above INR 1 lakh. Earlier rate was 0% cost calculated as closing price on Jan 31, 2018. #Dividend tax of 10% + Surcharge 12% + Cess 4% =11.648% Health & Education Cess of 4% introduced. Earlier, education Cess was 3%.

How to Invest in Best Equity Mutual Funds Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.

  2. Complete your Registration and KYC Process

  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest!

    Get Started

Conclusion

While looking for best equity mutual funds, investors should choose equity funds which are doing well in the market. One should know how a fund behaves and performs when the market goes bad. A deep analysis of fund’s last three years’ performances is an ideal way to buy one of the best equity mutual funds.

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
How helpful was this page ?
Rated 4.5, based on 84 reviews.
POST A COMMENT